Hypercalcaemia

{{Short description|High calcium (Ca2+) level in the blood serum}} {{cs1 config|name-list-style=vanc}} {{For|the disorder of low blood calcium|Hypocalcaemia}} {{Use British English|date=January 2021}} {{Use dmy dates|date=May 2026}}

{{Infobox medical condition (new) | name = Hypercalcaemia | synonyms = Hypercalcemia (US)<ref name="MeSH descriptor"/><ref name="SNOMED" /> | field = Endocrinology | symptoms = Abdominal pain, bone pain, confusion, depression, weakness<ref name=BMJ2015/><ref name=EU2010/> | complications = Kidney stones, abnormal heart rhythm, cardiac arrest<ref name=BMJ2015/><ref name=EU2010/> | onset = | duration = | types = | causes = Primary hyperparathyroidism, cancer, sarcoidosis, tuberculosis, Paget disease, multiple endocrine neoplasia, vitamin D toxicity<ref name=BMJ2015/><ref name=PMH2016/> | risks = | diagnosis = Blood serum level > 2.6 mmol/L (corrected calcium or ionised calcium)<ref name=BMJ2015/><ref name=EU2010/> | differential = | prevention = | treatment = Underlying cause, intravenous fluids, furosemide, calcitonin, pamidronate, haemodialysis<ref name=BMJ2015/><ref name=EU2010/> | medication = See article | prognosis = | frequency = 1-3 per 1,000 (hospital)<ref name=BMJ2015/><ref name="popstats">{{Cite journal |last=Tinawi |first=Mohammad |date=2021-01-01 |title=Disorders of Calcium Metabolism: Hypocalcaemia and Hypercalcaemia |journal=Cureus |volume=13 |issue=1 |article-number=e12420 |doi=10.7759/cureus.12420 |doi-access=free |issn=2168-8184 |pmc=7849212 |pmid=33542868}}</ref> 1-4% or 10-40 per 1,000 (general population)<ref name=popstats /> | deaths = }}

'''Hypercalcaemia''', also spelt '''hypercalcemia''' (US{{efn|see spelling differences between US and Commonwealth English}}),<ref name="MeSH descriptor">{{Cite web |title=MeSH Browser |url=https://meshb.nlm.nih.gov/record/ui?ui=D006934 |access-date=2026-04-12 |website=meshb.nlm.nih.gov}}</ref><ref name="SNOMED">{{Cite web |title=SNOMED CT, US Edition - Hypercalcemia - Classes |publisher=NCBO BioPortal |url=https://bioportal.bioontology.org/ontologies/SNOMEDCT?p=classes&conceptid=66931009 |access-date=2026-04-12 |website=bioportal.bioontology.org}}</ref><ref>{{Cite web |date=2026-05-19 |title=HYPERCALCAEMIA definition and meaning |publisher=Collins English Dictionary |url=https://www.collinsdictionary.com/dictionary/english/hypercalcaemia |access-date=2026-05-20 |website=www.collinsdictionary.com |language=en}}</ref> is a high calcium (Ca2+) level in the blood serum.<ref name="BMJ2015" /><ref name="PMH2016">{{cite web|author1=Pmhdev |title=Hypercalcaemia - National Library of Medicine|url=https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024710/|website=PubMed Health|access-date=27 September 2016|archive-url=https://web.archive.org/web/20170908183336/https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0024710/|archive-date=8 September 2017}}</ref> The normal range for total calcium is 2.1–2.6 mmol/L (8.8–10.7 mg/dL, 4.3–5.2 mEq/L), with levels greater than 2.6 mmol/L defined as hypercalcaemia.<ref name="BMJ2015" /><ref name="EU2010" /><ref name="SI2005">{{cite book |doi=10.1002/047009057X.app01 |chapter=Appendix 1: Conversion of SI Units to Standard Units |title=Principles and Practice of Geriatric Medicine |volume=2 |pages=i–ii |no-pp=yes |year=2005 |isbn=978-0-470-09057-2 }}</ref> Those with a mild increase that has developed slowly typically have no symptoms.<ref name="BMJ2015" /> In those with greater levels or rapid onset, symptoms may include abdominal pain, bone pain, confusion, depression, weakness, kidney stones or an abnormal heart rhythm including cardiac arrest.<ref name="BMJ2015" /><ref name="EU2010" />

Most outpatient cases are due to primary hyperparathyroidism and inpatient cases due to cancer.<ref name="BMJ2015" /> Other causes of hypercalcaemia include sarcoidosis, tuberculosis, Paget disease, multiple endocrine neoplasia (MEN), vitamin D toxicity, familial hypocalciuric hypercalcaemia, and certain medications, such as lithium and hydrochlorothiazide.<ref name="BMJ2015" /><ref name="EU2010">{{cite journal |doi=10.1016/j.resuscitation.2010.08.015 |pmid=20956045 |title=European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: Electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution |journal=Resuscitation |volume=81 |issue=10 |pages=1400–33 |year=2010 |last1=Soar |first1=Jasmeet |last2=Perkins |first2=Gavin D |last3=Abbas |first3=Gamal |last4=Alfonzo |first4=Annette |last5=Barelli |first5=Alessandro |last6=Bierens |first6=Joost J.L.M |last7=Brugger |first7=Hermann |last8=Deakin |first8=Charles D |last9=Dunning |first9=Joel |last10=Georgiou |first10=Marios |last11=Handley |first11=Anthony J |last12=Lockey |first12=David J |last13=Paal |first13=Peter |last14=Sandroni |first14=Claudio |last15=Thies |first15=Karl-Christian |last16=Zideman |first16=David A |last17=Nolan |first17=Jerry P }}</ref><ref name="PMH2016" /> Diagnosis should generally include either a corrected calcium or ionised calcium level and be confirmed after a week.<ref name=BMJ2015>{{cite journal |doi=10.1136/bmj.h2723 |pmid=26037642 |title=The diagnosis and management of hypercalcaemia |journal=BMJ |volume=350 |article-number=h2723 |year=2015 |last1=Minisola |first1=S |last2=Pepe |first2=J |last3=Piemonte |first3=S |last4=Cipriani |first4=C |s2cid=28462200 }}</ref> Specific changes, such as a shortened QT interval and prolonged PR interval, may be seen on an electrocardiogram (ECG).<ref name=EU2010/>

Treatment may include intravenous fluids, furosemide, calcitonin, intravenous bisphosphonate, in addition to treating the underlying cause.<ref name=BMJ2015/><ref name=EU2010/> The evidence for furosemide use, however, is poor.<ref name=BMJ2015/> In those with very high levels, hospitalisation may be required.<ref name=BMJ2015/> Haemodialysis may be used in those who do not respond to other treatments.<ref name=BMJ2015/> In those with vitamin D toxicity, steroids may be useful.<ref name=BMJ2015/> Hypercalcaemia is relatively common.<ref name=BMJ2015/> Primary hyperparathyroidism occurs in 1–7 per 1,000 people, and hypercalcaemia occurs in about 2.7% of those with cancer.<ref name=BMJ2015/>

==Signs and symptoms== {| class="wikitable" style = "float: right; margin-left:15px; text-align:center" |+ Mnemonic for symptoms |- | Stones || Kidney or biliary |- | Bones || Bone pain |- | Groans || Abdominal discomfort |- | Moans || Complaints of non-specific symptoms |- | Thrones || Constipation and excessive urination volume |- | Muscle tone || Muscle weakness, decreased reflexes |- | Psychiatric overtones || Depression, anxiety, cognitive dysfunction |}

The neuromuscular symptoms of hypercalcaemia are caused by a negative bathmotropic effect due to the increased interaction of calcium with sodium channels. Since calcium blocks sodium channels and inhibits depolarisation of nerve and muscle fibres, increased calcium raises the threshold for depolarisation.<ref name=CMArmstrong1999>{{cite journal |doi=10.1073/pnas.96.7.4154 |pmid=10097179 |pmc=22436 |title=Calcium block of Na+ channels and its effect on closing rate |journal=Proceedings of the National Academy of Sciences |volume=96 |issue=7 |pages=4154–7 |year=1999 |last1=Armstrong |first1=C. M |last2=Cota |first2=G |bibcode=1999PNAS...96.4154A |doi-access=free }}</ref> This results in decreased deep tendon reflexes (hyporeflexia), and skeletal muscle weakness.<ref name=Merck2017>{{cite web |url= http://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/electrolyte-disorders/hypercalcemia |title= Hypercalcaemia |publisher= Merck Manual |access-date= June 10, 2017 |url-status= live |archive-url= https://web.archive.org/web/20170713041445/https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/electrolyte-disorders/hypercalcemia |archive-date= July 13, 2017 }}</ref>

Other symptoms include cardiac arrhythmias (especially in those taking digoxin), fatigue, nausea, vomiting (emesis), loss of appetite, abdominal pain, and paralytic ileus. If kidney impairment occurs as a result, manifestations can include increased urination, urination at night, and increased thirst.<ref name=Merck2017/> Psychiatric manifestation can include emotional instability, confusion, delirium, psychosis, and stupor.<ref name=Merck2017/> Calcium deposits known as limbus sign may be visible in the eyes.<ref>Orient, Dr. Jane M. (2011). [https://www.amazon.com/gp/product/B0052TGRBK/ Amazon Sapira's Art & Science of Bedside Diagnosis (Kindle Edition)] Lippincott Williams & Wilkins. Retrieved January 7, 2012.</ref>

Symptoms are more common at high calcium blood values (12.0 mg/dL or 3 mmol/L).<ref name=Merck2017/> Severe hypercalcaemia (above 15–16 mg/dL or 3.75–4 mmol/L) is considered a medical emergency: at these levels, coma and cardiac arrest can result. The high levels of calcium ions decrease the neuron membrane permeability to sodium ions, thus decreasing excitability, which leads to hypotonicity of smooth and striated muscle. This explains the fatigue, muscle weakness, low tone and sluggish reflexes in muscle groups. The sluggish nerves also explain drowsiness, confusion, hallucinations, stupor or coma. In the gut this causes constipation. Hypocalcaemia causes the opposite by the same mechanism.<ref>{{cite web |url=https://www.lecturio.com/concepts/hypercalcemia/| title=Hypercalcaemia|website=The Lecturio Medical Concept Library |access-date= 25 July 2021}}</ref>

===Hypercalcaemic crisis {{anchor|crisis}}=== A hypercalcaemic crisis is an emergency situation with a severe hypercalcaemia, generally above approximately 14 mg/dL (or 3.5 mmol/L).<ref>[http://emedicine.medscape.com/article/766373-overview Hypercalcaemia in Emergency Medicine] {{webarchive|url=https://web.archive.org/web/20110425092016/http://emedicine.medscape.com/article/766373-overview |date=2011-04-25 }} at Medscape. Author: Robin R Hemphill. Chief Editor: Erik D Schraga. Retrieved April 2011</ref>

The main symptoms of a hypercalcaemic crisis are oliguria or anuria, as well as somnolence or coma.<ref name=Ziegler2001>{{cite journal |author=Ziegler R |title=Hypercalcaemic crisis |journal=J. Am. Soc. Nephrol. |volume=12 |pages=S3–9 |date=February 2001 |issue=Suppl 17 |doi=10.1681/ASN.V12suppl_1s3 |pmid=11251025 |doi-access=free }}</ref> After recognition, primary hyperparathyroidism should be proved or excluded.<ref name=Ziegler2001/>

In extreme cases of primary hyperparathyroidism, removal of the parathyroid gland after surgical neck exploration is the only way to avoid death.<ref name=Ziegler2001/> The diagnostic program should be performed within hours, in parallel with measures to lower serum calcium.<ref name=Ziegler2001/> Treatment of choice for acutely lowering calcium is extensive hydration and calcitonin, as well as bisphosphonates (which have effect on calcium levels after one or two days).<ref>[https://books.google.com/books?id=LngD6RFXY_AC&pg=PA394 Page 394] {{webarchive|url=https://web.archive.org/web/20170908183336/https://books.google.com/books?id=LngD6RFXY_AC&pg=PA394 |date=2017-09-08 }} in: {{cite book |author1=Roenn, Jamie H. Von |author2=Ann Berger |author3=Shuster, John W. |title=Principles and practice of palliative care and supportive oncology |publisher=Lippincott Williams & Wilkins |location=Hagerstwon, MD |year=2007 |isbn=978-0-7817-9595-1 }}</ref>

==Causes== Primary hyperparathyroidism and malignancy account for about 90% of cases of hypercalcaemia.<ref name=Kumar>Table 20-4 in: {{cite book |author1=Mitchell, Richard Sheppard |author2=Kumar, Vinay |author3=Abbas, Abul K. |author4=Fausto, Nelson |title=Robbins Basic Pathology|publisher=Saunders |location=Philadelphia |isbn=978-1-4160-2973-1 |edition=8th |year=2007 }}{{page needed|date=June 2018}}</ref><ref name="isbn0-07-147247-9">{{cite book |author1=Tierney, Lawrence M. |author2=McPhee, Stephen J. |author3=Papadakis, Maxine A. |title=Current Medical Diagnosis and Treatment 2007 (Current Medical Diagnosis and Treatment) |publisher=McGraw-Hill Professional |year=2006 |page=[https://archive.org/details/currentmedicaldi0046unse/page/901 901] |isbn=978-0-07-147247-0 |url=https://archive.org/details/currentmedicaldi0046unse/page/901 }}</ref>

Causes of hypercalcaemia can be divided into those that are PTH dependent or PTH independent.

===Parathyroid function=== * Primary hyperparathyroidism ** Solitary parathyroid adenoma<ref>{{cite journal |vauthors=Sekine O, Hozumi Y, Takemoto N, Kiyozaki H, Yamada S, Konishi F |title=Parathyroid adenoma without hyperparathyroidism |journal=Japanese Journal of Clinical Oncology |volume=34 |issue=3 |pages=155–8 |date=March 2004 |pmid=15078912 |doi=10.1093/jjco/hyh028|doi-access=free }}</ref> ** Primary parathyroid hyperplasia<ref name="Ranaghan 2018">{{Cite journal |last1=Renaghan |first1=Amanda DeMauro |last2=Rosner |first2=Mitchell H |date=2018-04-01 |title=Hypercalcaemia: etiology and management |url=https://academic.oup.com/ndt/article/33/4/549/4958946 |journal=Nephrology Dialysis Transplantation |language=en |volume=33 |issue=4 |pages=549–551 |doi=10.1093/ndt/gfy054 |issn=0931-0509|doi-access=free }}</ref> ** Parathyroid carcinoma<ref>Hu MI, Vassilopoulou-Sellin R, Lustig R, Lamont JP. [http://www.cancernetwork.com/cancer-management-11/chapter05/article/10165/1402668 "Thyroid and Parathyroid Cancers"] {{Webarchive|url=https://web.archive.org/web/20100228072652/http://www.cancernetwork.com/cancer-management-11/chapter05/article/10165/1402668 |date=2010-02-28 }} in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds) [http://www.cancernetwork.com/cancer-management-11/ Cancer Management: A Multidisciplinary Approach] {{Webarchive|url=https://web.archive.org/web/20131004224102/http://www.cancernetwork.com/cancer-management-11/ |date=2013-10-04 }}. 11 ed. 2008.</ref> ** Multiple endocrine neoplasia (MEN1 & MEN2A)<ref>{{cite web |url= https://www.lecturio.com/concepts/multiple-endocrine-neoplasia/| title= Multiple Endocrine Neoplasia |website=The Lecturio Medical Concept Library |access-date= 11 August 2021}}</ref> ** Familial isolated hyperparathyroidism<ref>{{OMIM|146200}}</ref> * Lithium use * Familial hypocalciuric hypercalcaemia/familial benign hypercalcaemia<ref>{{OMIM|145980}}</ref><ref>{{OMIM|145981}}</ref><ref>{{OMIM|600740}}</ref>

===Cancer=== Hypercalcaemia of malignancy (cancer) is due to a variety of mechanisms. The two most common are humoral hypercalcaemia of malignancy and local osteolytic hypercalcaemia due to bony metastasis. Humoral hypercalcaemia of malignancy involves the tumour releasing a hormone which increases calcium mobilisation (most commonly parathyroid hormone-related protein (PTHrP)) into the circulation.<ref name="Guise 2022">{{cite journal |last1=Guise |first1=Theresa A. |last2=Wysolmerski |first2=John J. |title=Cancer-Associated Hypercalcaemia |journal=New England Journal of Medicine |date=14 April 2022 |volume=386 |issue=15 |pages=1443–1451 |doi=10.1056/NEJMcp2113128|pmid=35417639 |s2cid=248155661 }}</ref> PTHrP acts similarly to parathyroid hormone in that it binds to the parathyroid hormone 1 receptors on the kidneys and bones and causes an increased tubular reabsorption of calcium and activation of osteoclast activity, respectively.<ref name="Guise 2022" /> Osteoclasts are a type of bone cell which cause bone resorption, releasing calcium into the bloodstream. PTHrP also acts by activating rank ligand and inhibiting osteoprotegerin which activates nuclear factor kappa B, which causes further activation of osteoclast activity.<ref name="Guise 2022" /> The combination of PTHrP driven osteoclast activation and calcium reabsorption by the kidneys causes hypercalcaemia associated with malignancy (humoral type).<ref name="Guise 2022" />

Another mechanism in which cancer causes hypercalcaemia is via local osteolysis due to metastasis to bone.<ref name="Guise 2022" /> Tumor bone metastasis releases local cytokines including IL-6, IL-8, IL-11, interleukin-1 beta, TNF alpha, and macrophage inflammatory protein. These cytokines activate osteoclasts and inhibit osteoblasts (the cell type responsible for laying down new bone) via the rank ligand pathway leading to bone resorption and calcium release into the bloodstream.<ref name="Guise 2022" /> The massive release of calcium from bone metastasis and osteoclast activation usually overwhelms the kidney's ability to secrete calcium, thus leading to hypercalcaemia.<ref name="Guise 2022" />

Hypercalcaemia of malignancy may also occur due to tumour production of vitamin D or parathyroid hormone. These causes are rare and constitute about 1% of all causes of hypercalcaemia of malignancy.<ref name="Guise 2022" />

Hypercalcaemia of malignancy usually portends a poor prognosis, and the medial survival is 25–52 days of its development.<ref name="Guise 2022" /> It has an incidence of 30% in those with cancer, and the prevalence is estimated to be about 2-3% in the United States.<ref name="Guise 2022" />

[[Image:Small cell carcinoma of the ovary hypercalcemic type - high mag.jpg|thumb|right|Micrograph of ovarian small cell carcinoma of the hypercalcaemic type. H&E stain.]]

Common cancer types that are associated with hypercalcaemia of malignancy include: * Solid tumour with metastasis via local osteolytic hypercalcaemia: which can be due to any tumour that metastasises to the bone. But common causes include breast cancer, lung cancer, kidney cancer, and myeloma or lymphoma of the bone<ref name="Guise 2022" /> * Solid tumour with humoral mediation of hypercalcaemia: lung cancer (especially squamous cell tumours, a type of non-small cell lung cancer), squamous cell cancers of the head and neck, kidney cancer or other urothelial cancers, and breast cancer.<ref name="Guise 2022" /> * Haematologic cancers: including multiple myeloma, lymphoma, leukaemia * Ovarian small cell carcinoma of the hypercalcaemic type

===Vitamin-D disorders=== * Hypervitaminosis D (vitamin D intoxication) * Elevated 1,25(OH)2D (see calcitriol under Vitamin D) levels (e.g., sarcoidosis and other granulomatous diseases such as tuberculosis, berylliosis, histoplasmosis, Crohn's disease, and granulomatosis with polyangiitis) * Idiopathic hypercalcaemia of infancy<ref>{{OMIM|143880}}</ref> * Rebound hypercalcaemia after rhabdomyolysis

===High bone-turnover=== * Hyperthyroidism * Multiple myeloma * Prolonged immobilisation * Paget's disease * Thiazide use * Vitamin A intoxication<ref name="Ranaghan 2018"/>

===Kidney failure=== * Tertiary hyperparathyroidism * Aluminium intoxication * Milk-alkali syndrome<ref name="Ranaghan 2018"/>

===Other=== * Acromegaly * Adrenal insufficiency * Zollinger–Ellison syndrome * Williams Syndrome * Excessive calcium consumption

==Diagnosis== Diagnosis should generally include either a calculation of corrected calcium or direct measurement of ionised calcium level and be confirmed after a week.<ref name=BMJ2015/> This is because either high or low serum albumin levels does not show the true levels of ionised calcium.<ref name="Ranaghan 2018"/> There is, however, controversy around the usefulness of corrected calcium as it may be no better than total calcium.<ref>{{cite book |last1=Thomas |first1=Lynn K. |last2=Othersen |first2=Jennifer Bohnstadt |title=Nutrition Therapy for Chronic Kidney Disease |date=2016 |publisher=CRC Press |isbn=978-1-4398-4950-7 |page=116 |url=https://books.google.com/books?id=o3bRBQAAQBAJ&pg=PA116 |language=en}}</ref>

Once calcium is confirmed to be elevated, a detailed history taken from the subject, including review of medications, any vitamin supplementations, herbal preparations, and previous calcium values. Chronic elevation of calcium with absent or mild symptoms often points to primary hyperparathyroidism or familial hypocalciuric hypercalcaemia. For those who has underlying malignancy, the cancers may be sufficiently severe to show up in history and examination to point towards the diagnosis with little laboratory investigations.<ref name="Ranaghan 2018"/>

If detailed history and examination does not narrow down the differential diagnoses, further laboratory investigations are performed. Intact PTH (iPTH, biologically active parathyroid hormone molecules) is measured with immunoradiometric or immunochemoluminescent assay. Elevated (or high-normal) iPTH with high urine calcium/creatinine ratio (more than 0.03) is suggestive of primary hyperparathyroidism, usually accompanied by low serum phosphate. High iPTH with low urine calcium/creatinine ratio is suggestive of familial hypocalciuric hypercalcaemia. Low iPTH should be followed up with Parathyroid hormone-related protein (PTHrP) measurements (though not available in all labs). Elevated PTHrP is suggestive of malignancy. Normal PTHrP is suggestive of multiple myeloma, vitamin A excess, milk-alkali syndrome, thyrotoxicosis, and immobilisation. Elevated Calcitriol is suggestive of lymphoma, sarcoidosis, granulomatous disorders, and excessive calcitriol intake. Elevated calcifediol is suggestive of vitamin D or excessive calcifediol intake.<ref name="Ranaghan 2018"/>

The normal range is 2.1–2.6 mmol/L (8.8–10.7 mg/dL, 4.3–5.2 mEq/L), with levels greater than 2.6 mmol/L defined as hypercalcaemia.<ref name=BMJ2015/><ref name=EU2010/><ref name=SI2005/> Moderate hypercalcaemia is a level of 2.88–3.5 mmol/L (11.5–14 mg/dL) while severe hypercalcaemia is > 3.5 mmol/L (>14 mg/dL).<ref>{{cite book |last1=Stack |first1=Brendan C. Jr. |last2=Bodenner |first2=Donald L. |title=Medical and Surgical Treatment of Parathyroid Diseases: An Evidence-Based Approach |date=2016 |publisher=Springer |isbn=978-3-319-26794-4 |page=99 |url=https://books.google.com/books?id=p1C7DQAAQBAJ&pg=PA99 |language=en}}</ref>

===ECG=== thumb|An Osborn wave, an abnormal EKG tracing that can be associated with hypercalcaemia.

Abnormal heart rhythms can also result, and ECG findings of a short QT interval<ref>{{cite web |url=http://lifeinthefastlane.com/ecg-library/basics/hypercalcaemia/ |title=Life in the Fast Lane • LITFL |access-date=2014-10-19 |url-status=live |archive-url=https://web.archive.org/web/20141216085448/http://lifeinthefastlane.com/ecg-library/basics/hypercalcaemia |archive-date=2014-12-16 }}</ref> suggest hypercalcaemia. Significant hypercalcaemia can cause ECG changes mimicking an acute myocardial infarction.<ref>{{Cite journal | doi = 10.7861/clinmedicine.9-2-186 | last1 = Wesson | first1 = L | last2 = Suresh | first2 = V | last3 = Parry | first3 = R | title = Severe hypercalcaemia mimicking acute myocardial infarction | journal = Clinical Medicine | volume = 9 | issue = 2 | pages = 186–7 | year = 2009 | pmid = 19435131| pmc = 4952678 }}</ref> Hypercalcaemia has also been known to cause an ECG finding mimicking hypothermia, known as an Osborn wave.<ref>{{cite journal |doi=10.3402/jchimp.v1i4.10742 |pmid=23882340 |pmc=3714046 |title=Osborn waves in a hypothermic patient |journal=Journal of Community Hospital Internal Medicine Perspectives |volume=1 |issue=4 |article-number=10742 |year=2012 |last1=Serafi |first1=Sami W |last2=Vliek |first2=Crystal |last3=Taremi |first3=Mahnaz }}</ref>

==Treatments== The goal of therapy is to treat the hypercalcaemia first and subsequently effort is directed to treat the underlying cause. In those with a calcium level above 13 mg/dL, calcium level that is rising rapidly or those with altered mental status, urgent treatment is required.<ref name="Guise 2022" />

===Fluids and diuretics=== Initial therapy:{{citation needed|date=November 2021}} ** IV fluids is the initial therapy.<ref name="Guise 2022" /> Hypercalcaemia usually causes symptoms that lead to chronic dehydration, such as nausea, vomiting, anorexia, and nephrogenic diabetes insipidus (inability of the kidney to concentrate the urine). IV fluid rehydration allows the kidneys to excrete more calcium, and usually lowers the calcium level by 1–2 mg/dL.<ref name="Guise 2022" /> ** increased salt intake also can increase body fluid volume as well as increasing urine sodium excretion, which further increases urinary calcium excretion. ** after rehydration, a loop diuretic such as furosemide can be given to permit continued large volume intravenous salt and water replacement while minimising the risk of blood volume overload and pulmonary oedema. In addition, loop diuretics tend to depress calcium reabsorption by the kidney thereby helping to lower blood calcium levels ** caution must be taken to prevent potassium or magnesium depletion

===Bisphosphonates and calcitonin=== Additional therapy:{{citation needed|date=November 2021}} * bisphosphonates are pyrophosphate analogues with high affinity for bone, especially areas of high bone-turnover. ** they are taken up by osteoclasts and inhibit osteoclastic bone resorption, therefore inhibiting calcium release from osteoclasts ** current available drugs include: (1st generation) etidronate, (2nd generation) tiludronate, IV pamidronate, alendronate (3rd generation) zoledronate and risedronate ** Bisphosphonates are used as a first line therapy for those with hypercalcaemia of malignancy. They are used as both an acute therapy and are usually continued long term to prevent hypercalcaemia.<ref name="Guise 2022" /> ** Bisphosphonates are not recommended in those with chronic kidney disease or those who are severely dehydrated as they may worsen or cause kidney disease.<ref name="Guise 2022" /> ** Bisphosphonates caused normalisation of calcium levels in 60-90% of patients who were treated for hypercalcaemia of malignancy.<ref name="Guise 2022" /> * Denosumab is a bone anti-resorptive agent that can be used to treat hypercalcaemia in patients with a contraindication to bisphosphonates such as severe kidney failure or allergy. ** Denosumab is a monoclonal antibody that inhibits osteoclasts. It acts by binding RANK ligand preventing it from activating osteoclasts via NFKB.<ref name="Guise 2022" /> ** Denosumab caused normalisation of calcium levels in 70% in those with hypercalcaemia of malignancy.<ref name="Guise 2022" /> * Calcitonin blocks bone resorption by inhibiting osteoclasts and also increases urinary calcium excretion by the kidneys.<ref name="Guise 2022" /> ** Usually used in life-threatening hypercalcaemia along with rehydration, diuresis, and bisphosphonates ** Due to its limited duration of action (it works for 48–96 hours, then efficacy decreases as the calcitonin receptors are down-regulated) its use is limited to acute hypercalcaemia as a bridge therapy until more long-term treatments can be initiated.<ref name="Guise 2022" />

===Other therapies=== * rarely used, or used in special circumstances: ** plicamycin inhibits bone resorption (rarely used) ** gallium nitrate inhibits bone resorption and changes structure of bone crystals (rarely used) ** glucocorticoids increase urinary calcium excretion and decrease intestinal calcium absorption *** no effect on calcium level in normal or primary hyperparathyroidism *** effective in hypercalcaemia due to malignancy with elevated vitamin D levels (many types of malignancies raise the vitamin D level).<ref name="Guise 2022" /> *** also effective in hypervitaminosis D and sarcoidosis ** dialysis usually used in severe hypercalcaemia complicated by kidney failure. Supplemental phosphate should be monitored and added if necessary ** phosphate therapy can correct the hypophosphataemia in the face of hypercalcaemia and lower serum calcium, but this can further increase the risk for kidney stones and nephrocalcinosis

==Other animals== Research has led to a better understanding of hypercalcaemia in non-human animals. Often the causes of hypercalcaemia have a correlation to the environment in which the organisms live. Hypercalcaemia in house pets is typically due to disease, but other cases can be due to accidental ingestion of plants or chemicals in the home.<ref name="Hypercalcaemia in Dogs and Cats" /> Outdoor animals commonly develop hypercalcaemia through vitamin D toxicity from wild plants within their environments.<ref name="Enzootic Calcinosis">[http://www.merckmanuals.com/vet/musculoskeletal_system/dystrophies_associated_with_calcium_phosphorus_and_vitamin_d/enzootic_calcinosis.html Enzootic Calcinosis] {{webarchive|url=https://web.archive.org/web/20140728125957/http://www.merckmanuals.com/vet/musculoskeletal_system/dystrophies_associated_with_calcium_phosphorus_and_vitamin_d/enzootic_calcinosis.html |date=2014-07-28 }} Gruenberg MS, PhD, DECAR DECBHM. W.G., April 2014. Enzootic Calcinosis. The Merck Veterinary Manual. Merck Sharp & Dohme, Whitehouse Station, NJ, USA.</ref>

===Household pets=== Household pets such as dogs and cats are found to develop hypercalcaemia. It is less common in cats, and many feline cases are idiopathic.<ref name="Hypercalcaemia in Dogs and Cats" /> In dogs, lymphosarcoma, Addison's disease, primary hyperparathyroidism, and chronic kidney failure are the main causes of hypercalcaemia, but there are also environmental causes usually unique to indoor pets.<ref name="Hypercalcaemia in Dogs and Cats">[http://www.merckmanuals.com/vet/endocrine_system/the_parathyroid_glands_and_disorders_of_calcium_metabolism/hypercalcemia_in_dogs_and_cats.html Hypercalcaemia in Dogs and Cats] {{webarchive|url=https://web.archive.org/web/20140728125538/http://www.merckmanuals.com/vet/endocrine_system/the_parathyroid_glands_and_disorders_of_calcium_metabolism/hypercalcemia_in_dogs_and_cats.html |date=2014-07-28 }} Peterson DVM, DACVIM. M. E., July 2013. Hypercalcaemia in Dogs and Cats. The Merck Veterinary Manual. Merck Sharp & Dohme, Whitehouse Station, NJ, USA.</ref> Ingestion of small amounts of calcipotriene found in psoriasis cream can be fatal to a pet.<ref name="Topical Agents (Toxicity)">[http://www.merckmanuals.com/vet/toxicology/toxicities_from_human_drugs/topical_agents_toxicity.html Topical Agents (Toxicity)] {{webarchive|url=https://web.archive.org/web/20140728125702/http://www.merckmanuals.com/vet/toxicology/toxicities_from_human_drugs/topical_agents_toxicity.html |date=2014-07-28 }} Khan DVM, MS, PhD, DABVT, S.A., March 2012. Topical Agents (Toxicity). The Merck Veterinary Manual. Merck Sharp & Dohme, Whitehouse Station, NJ, USA.</ref> Calcipotriene causes a rapid rise in calcium ion levels.<ref name="Topical Agents (Toxicity)" /> Calcium ion levels can remain high for weeks if untreated and lead to an array of medical issues.<ref name="Topical Agents (Toxicity)" /> There are also cases of hypercalcaemia reported due to dogs ingesting rodenticides containing a chemical similar to calcipotriene found in psoriasis cream.<ref name="Topical Agents (Toxicity)" /> Additionally, ingestion of household plants is a cause of hypercalcaemia. Plants such as ''Cestrum diurnum'', and ''Solanum malacoxylon'' contain ergocalciferol or cholecalciferol which cause the onset of hypercalcaemia.<ref name="Hypercalcaemia in Dogs and Cats" /> Consuming small amounts of these plants can be fatal to pets. Observable symptoms may develop such as polydipsia, polyuria, extreme fatigue, or constipation.<ref name="Hypercalcaemia in Dogs and Cats" />

===Outdoor animals=== [[File:Trisetum.flavescens2.-.lindsey.jpg|thumb|''Trisetum flavescens'' (yellow oat grass)]]

In certain outdoor environments, animals such as horses, pigs, cattle, and sheep experience hypercalcaemia commonly. In southern Brazil and Mattewara India, approximately 17% of sheep are affected, with 60% of these cases being fatal.<ref name="Enzootic Calcinosis" /> Many cases are also documented in Argentina, Papua New Guinea, Jamaica, Hawaii, and Bavaria.<ref name="Enzootic Calcinosis" /> These cases of hypercalcaemeia are usually caused by ingesting ''Trisetum flavescens'' before it has dried out.<ref name="Enzootic Calcinosis" /> Once ''Trisetum flavescens'' is dried out, the toxicity of it is diminished.<ref name="Enzootic Calcinosis" /> Other plants causing hypercalcaemia are ''Cestrum diurnum'', ''Nierembergia veitchii'', ''Solanum esuriale'', ''Solanum torvum'', and ''Solanum malacoxylon''.<ref name="Enzootic Calcinosis" /> These plants contain calcitriol or similar substances that cause rises in calcium ion levels.<ref name="Enzootic Calcinosis" /> Hypercalcaemia is most common in grazing lands at altitudes above 1500 meters where growth of plants like ''Trisetum flavescens'' is favourable.<ref name="Enzootic Calcinosis" /> Even if small amounts are ingested over long periods of time, the prolonged high levels of calcium ions have large negative effects on the animals.<ref name="Enzootic Calcinosis" /> The issues these animals experience are muscle weakness, and calcification of blood vessels, heart valves, liver, kidneys, and other soft tissues, which eventually can lead to death.<ref name="Enzootic Calcinosis" />

== Notes == {{notelist}}

==References== {{Reflist}}

== External links == {{Medical resources | DiseasesDB = 6196 | ICD10 = {{ICD10|E|83|5|e|70}} | ICD9 = {{ICD9|275.42}} | ICDO = | OMIM = | MedlinePlus = 000365 | eMedicineSubj = med | eMedicineTopic = 1068 | eMedicine_mult = {{eMedicine2|emerg|260}} {{eMedicine2|ped|1062}} | MeshID = D006934 | SNOMED CT = 66931009 }}

Category:Electrolyte disturbances Category:Calcium Category:Abnormal clinical and laboratory findings for blood Category:Wikipedia medicine articles ready to translate Category:Wikipedia neurology articles ready to translate Category:Medical mnemonics